Restoring FDA’s Confidence In Labeling
This article was originally published in RPM Report
Executive Summary
FDA’s decision to harmonize immediate-release and extended-release opioid labeling is an important step to address a political vulnerability for the agency and its new commissioner. But Commissioner Califf’s discussion of the role of FDA-approved labeling may be more important as an indicator of the overall drug approval climate – and a path forward in the thicket of First Amendment challenges to the agency’s marketing oversight.
You may also be interested in...
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.